

Mediclinic Intl plc - Replacement Director/PDMR Shareholding

July 31, 2020

RNS Number : 8010U

Mediclinic International plc

31 July 2020

Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
ISIN: GB00B8HX8Z88
LEI: 2138002S5BSBIZTD5I60
("Mediclinic", or the "Company", or the "Group")

31 July 2020

Replacement: The following announcement replaces the announcement released on 17 June 2020 at 3.30pm (UK) under RNS number 2768Q. The amount settled per share and the cash settlements (including dividend equivalents) have been amended. The corrected announcement is set out below and all other details remain unchanged.

NOTIFICATION OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

This notification sets out details of the vesting and settlement of awards granted to the executive directors on 15 June 2018 in respect of the deferred element of the Company's 2017 short-term incentive ("**STI**"). These awards, denominated in shares, vested on 15 June 2020 and will be settled in cash on 26 June 2020 based on the middle-market quotation of a share on 15 June 2020, being £2.68 per share. The amount settled included the value of dividends attributable to the vested shares during the period between the date of grant and the date of vesting, being a total of 15.8 pence per share.

The table below sets out the number of shares vested for the directors who were granted awards under the STI on 15 June 2018 together with the corresponding cash settlement.

Name	Number of shares vested	Cash settlement (including dividend equivalents)
Petrus Jurgens Myburgh ¹	27 236	£77,350
Daniël Petrus Meintjes ²	45 811	£130,103

Notes:

¹ As Group Chief Financial Officer, Mr Myburgh is required to build and maintain a minimum holding of shares equivalent to a value of 200% of his annual base compensation. As that threshold had not been met under the Company's Remuneration Policy, Mr Myburgh was required to apply 50% of the net of tax value of the vested shares to the purchase of ordinary shares in Mediclinic. As announced on 10 June 2020, Mr Myburgh purchased 7 500 shares on 8 June 2020 to fulfil this obligation.

² Mr Meintjes was an executive director of the Company at the time the award was granted and is now a non-executive director.

The notifications below are made in accordance with Articles 19.1 and 19.3 of the Market Abuse Regulation.

1.	Details of PDMR / person closely associated with them ("PCA")					
a)	Name	Petrus Jurgens Myburgh				
2.	Reason for the notification					
a)	Position / status	Group Chief Financial Officer of the Company				
b)	Initial notification / amendment	Initial Notification				
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor					
a)	Name	Mediclinic International plc				
b)	LEI	2138002S5BSBIZTD5160				
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted					
a)	Description of the financial instrument Identification Code	Ordinary shares GB00B8HX8Z88				
b)	Nature of the transaction	Vesting and cash settlement of award over ordinary shares in Mediclinic International plc granted in 2018 under the Company's short-term incentive scheme				
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>£nil</td> <td>27 236</td> </tr> </tbody> </table>	Price(s)	Volume(s)	£nil	27 236
Price(s)	Volume(s)					
£nil	27 236					
d)	Aggregated information Aggregated volume Price	27 236 £nil				
e)	Date of the transaction	15 June 2020				
f)	Place of the transaction	Outside a trading venue				

1.	Details of PDMR / person closely associated with them ("PCA")					
a)	Name	Daniël Petrus Meintjes				
2.	Reason for the notification					
a)	Position / status	Non-executive director of the Company				
b)	Initial notification / amendment	Initial Notification				
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor					
a)	Name	Mediclinic International plc				
b)	LEI	2138002S5BSBIZTD5160				
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted					
a)	Description of the financial instrument Identification Code	Ordinary shares GB00B8HX8Z88				
b)	Nature of the transaction	Vesting and cash settlement of award over ordinary shares in Mediclinic International plc granted in 2018 under the Company's short-term incentive scheme				
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>£nil</td> <td>45 811</td> </tr> </tbody> </table>	Price(s)	Volume(s)	£nil	45 811
Price(s)	Volume(s)					
£nil	45 811					
d)	Aggregated information Aggregated volume Price	45 811 £nil				
e)	Date of the transaction	15 June 2020				
f)	Place of the transaction	Outside a trading venue				

About Mediclinic International plc

Mediclinic is a diversified international private healthcare services group, established in South Africa in 1983, with divisions in Switzerland, Southern Africa (South Africa and Namibia) and the United Arab Emirates ("UAE").

The Group's core purpose is to enhance the quality of life.

Its vision is to be the partner of choice that people trust for all their healthcare needs.

Mediclinic is focused on providing specialist-orientated, multi-disciplinary services across the continuum of care in such a way that the Group will be regarded as the most respected and trusted provider of healthcare services by patients, medical practitioners, funders and regulators of healthcare in each of its markets.

At 1 July 2020, Mediclinic comprised 76 hospitals, eight sub-acute and specialised hospitals, 15 day case clinics and 18 outpatient clinics. Hirslanden operated 17 hospitals and three day case clinics in Switzerland with more than 1 800 inpatient beds; Mediclinic Southern Africa operations included 52 hospitals (three of which in Namibia), eight sub-acute and specialised hospitals and 10 day case clinics (four of which operated by Intercare) across South Africa, and more than 8 700 inpatient beds; and Mediclinic Middle East operated seven hospitals, two day case clinics and 18 outpatient clinics with more than 900 inpatient beds in the UAE.

The Company's primary listing is on the London Stock Exchange ("**LSE**") in the UK, with secondary listings on the JSE Ltd in South Africa and the Namibian Stock Exchange in Namibia.

Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, a leading private healthcare group based in the UK and listed on the LSE.

For further information, please contact:

Company Secretary, Link Company Matters Limited

Kerry Higgins
+44 (0) 20 7954 9583

Investor Relations, Mediclinic International plc

James Arnold, Head of Investor Relations
ir@mediclinic.com
+44 (0)20 3786 8181

Media queries

FTI Consulting
Ben Atwell/Ciara Martin - UK
+44 (0)20 3727 1000
Sherryn Schooling - South Africa
+27 (0)21 487 9000

Registered address: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom

Website: www.mediclinic.com

Corporate broker: Morgan Stanley & Co International plc and UBS Investment Bank
JSE sponsor (South Africa): Rand Merchant Bank (A division of FirstRand Bank Limited)

NSX sponsor (Namibia): Simonis Storm Securities (Pty) Ltd

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

DSHWPUAAMUPUGGG